GMR Solutions Inc. (GMRS) is the largest emergency medical services provider in the United States, operating the American Medical Response ground fleet and the Air Evac Lifeteam, REACH, Guardian Flight, Med-Trans and AirMed International air-medical businesses across roughly 1,400 counties. The company listed on the New York Stock Exchange in May 2026 at $15 per share and now trades well below that offering price. On Thursday, the stock changed hands at $10.10, a decline of 5.74% from the prior session's close of $10.71. The move was decisively to the downside. No fresh company press release, filing or wire report issued before the open accounted for the size of the drop, leaving the session's selling tied to continuing fallout from the third-quarter report and a run of mildly negative analyst and insider signals.
The dominant driver remains the market's read on results published after the close on Nov. 9. GMR reported third-quarter revenue of $1.60 billion, up 5.9%, adjusted earnings of $0.64 per share against a consensus near $0.47, and net income of $135.6 million, up 81.7%. The headline beat, however, was powered largely by a lower interest burden following debt redemption and a term-loan repricing, not by underlying demand. Adjusted EBITDA advanced just 4.2% to $356.6 million, same-market revenue growth slowed to about 6%, and management maintained rather than raised full-year guidance. Shares gapped higher on Nov. 10 and then reversed sharply, and the stock has not recovered. Thursday's action is consistent with that same re-rating: investors are valuing a capital-structure story, not an operating growth story.
Citi lowered its price target on the shares to $15 from $17 on Nov. 11 while retaining a Buy rating, a modest trim that nonetheless reinforced the view that near-term upside is narrower than previously modeled. Separately, insider selling has been persistent. The chief executive, chief financial officer, president, general counsel and chief accounting officer have all reported sales over recent months, and a fresh filing on Nov. 18 disclosed an additional sale of 90,000 shares by the president and chief operating officer. None of these disclosures is individually material for a company with roughly 90 million shares outstanding, but the absence of offsetting open-market purchases has weighed on sentiment in a thinly traded, recently listed name.
The balance sheet remains the central debate. GMR carries about $4 billion of net debt against an equity market value of roughly $0.9 billion, putting enterprise value near $5.3 billion, while a rising share of transport revenue comes from lower-reimbursement Medicare and Medicaid programs. With interest coverage near 2.3 times and capital spending needs in aircraft and fleet renewal, the equity is sensitive to small changes in reimbursement rates, fuel costs and transport volumes. Thursday's selling reflects that sensitivity rather than a new disclosure.
The decline looked idiosyncratic rather than sector-driven, with no industry-wide development identified in the healthcare provider space before the open. Liquidity is thin: average daily turnover runs near 1 million shares, and each of the past seven sessions has seen 1 million to 3.2 million shares change hands, a marked pickup that points to active repositioning. Technically, the shares broke below their 50-day moving average around $11.10 and surrendered the $11 handle, leaving the October low near $9.42 as the next reference point. The stock sits roughly 37% below its 52-week high of $15.98 and about 12% above its low of $8.99.
The score runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news and an extreme, rare price move. GMRS scores 25 out of 100. The verified news backdrop is modest: an earnings beat that disappointed on quality, a single price-target trim, routine insider filings and a conference-scheduling release, none of which is large relative to a company with $6 billion in annual revenue.
The price move was likewise unremarkable by this stock's standards. Thursday's 5.74% decline was about twice the typical 2.9% absolute daily change of the past 60 sessions, and six of those sessions produced moves of equal or greater size, including three drops of more than 7%. Weak catalysts and an ordinary-for-this-name swing combine into a low score.
Attention turns to the December conference circuit, with management scheduled to present at the Evercore healthcare conference on Dec. 1 and to meet investors at Citi's healthcare conference on Dec. 2, followed by a leveraged finance conference appearance. Those sessions offer the first chance for updated commentary since the third quarter. Fourth-quarter and full-year 2026 results are expected in late February. Investors will focus on transport volume trends, same-market revenue growth, the trajectory of adjusted EBITDA margins against fuel and labor inflation, and progress on further debt reduction. Key risks include reimbursement pressure from public payors, integration and safety liabilities across the air-medical fleet, refinancing conditions on the term loan, and the possibility that post-IPO lockup expirations add supply. The bull case rests on a forward earnings multiple in the high single digits and free cash flow that remains robust relative to equity value.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the list changes as market conditions shift. For readers tracking volatile names like this one, it offers a structured way to see which automated strategies are currently working. Review the Trending AI Robots page to compare approaches.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Indicator for GMRS moved out of overbought territory on November 09, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 1 instances where the indicator moved out of the overbought zone. In 1 of the 1 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMRS as a result. In 4 of 6 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for GMRS turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 4 similar instances when the indicator turned negative. In 4 of the 4 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
GMRS moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for GMRS crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +3.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMRS advanced for three days, in 14 of 20 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
GMRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 9 of 14 cases where GMRS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.851) is normal, around the industry mean (204.532). P/E Ratio (-6.129) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.502) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. GMRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement